| Literature DB >> 25091665 |
Jagdish K Zade1, Prasad S Kulkarni2, Sajjad A Desai1, Rajendra N Sabale1, Sameer P Naik1, Rajeev M Dhere1.
Abstract
A bovine rotavirus pentavalent vaccine (BRV-PV) containing rotavirus human-bovine (UK) reassortant strains of serotype G1, G2, G3, G4 and G9 has been developed by the Serum Institute of India Ltd, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), USA. The vaccine underwent animal toxicity studies and Phase I and II studies in adults, toddlers and infants. It has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotavirus gastroenteritis.Entities:
Keywords: Bovine rotavirus pentavalent rotavirus vaccine (BRV-PV); Clinical trials; Development; Serum Institute of India Ltd.
Mesh：
Substances：
Year: 2014 PMID： 25091665 DOI： 10.1016/j.vaccine.2014.03.003
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641